EDITAS MEDICINE, INC. Operating Expenses
EDITAS MEDICINE, INC. (EDIT) reported Operating Expenses of $30.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- EDITAS MEDICINE, INC. operating expenses for the quarter ending 2026-06-30 was $30.44M, a 44.77% decline year-over-year.
- EDITAS MEDICINE, INC. operating expenses for the quarter ending 2026-03-31 was $27.83M, a 65.56% decline year-over-year.
- EDITAS MEDICINE, INC. operating expenses for the quarter ending 2025-12-31 was $32.50M, a 57.91% decline year-over-year.
- EDITAS MEDICINE, INC. operating expenses for the quarter ending 2025-09-30 was $32.09M, a 51.18% decline year-over-year.
- EDITAS MEDICINE, INC. operating expenses for fiscal 2025 was $200.53M, a 29.26% decline from fiscal 2024.
- EDITAS MEDICINE, INC. operating expenses for fiscal 2024 was $283.47M, a 14.62% increase from fiscal 2023.
- EDITAS MEDICINE, INC. operating expenses for fiscal 2023 was $247.30M, a 0.67% increase from fiscal 2022.
- EDITAS MEDICINE, INC. operating expenses for fiscal 2022 was $245.66M, a 12.33% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.44M 10-Q · filed 2026-08-05 | $58.28M 10-Q · filed 2026-08-05 | $90.77M derived: sum of 3 quarters · filed 2026-08-05 | $122.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $27.83M 10-Q · filed 2026-05-05 | $60.33M derived: sum of 2 quarters · filed 2026-05-05 | $92.42M derived: sum of 3 quarters · filed 2026-05-05 | $147.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $32.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $64.59M derived: sum of 2 quarters · filed 2026-03-09 | $119.71M derived: sum of 3 quarters · filed 2026-08-05 | $200.53M 10-K · filed 2026-03-09 |
| 2025-09-30 | $32.09M 10-Q · filed 2025-11-10 | $87.21M derived: sum of 2 quarters · filed 2026-08-05 | $168.03M 10-Q · filed 2025-11-10 | $245.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $55.12M 10-Q · filed 2026-08-05 | $135.94M 10-Q · filed 2026-08-05 | $213.14M derived: sum of 3 quarters · filed 2026-08-05 | $278.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $80.82M 10-Q · filed 2026-05-05 | $158.02M derived: sum of 2 quarters · filed 2026-05-05 | $223.75M derived: sum of 3 quarters · filed 2026-05-05 | $296.16M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $77.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $142.92M derived: sum of 2 quarters · filed 2026-03-09 | $215.34M derived: sum of 3 quarters · filed 2026-03-09 | $283.47M 10-K · filed 2026-03-09 |
| 2024-09-30 | $65.73M 10-Q · filed 2025-11-10 | $138.14M derived: sum of 2 quarters · filed 2025-11-10 | $206.27M 10-Q · filed 2025-11-10 | $290.28M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $72.42M 10-Q · filed 2025-08-12 | $140.54M 10-Q · filed 2025-08-12 | $224.55M derived: sum of 3 quarters · filed 2025-08-12 | $280.05M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $68.13M 10-Q · filed 2025-05-12 | $152.14M derived: sum of 2 quarters · filed 2025-05-12 | $207.64M derived: sum of 3 quarters · filed 2025-05-12 | $254.62M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $84.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $139.51M derived: sum of 2 quarters · filed 2025-03-05 | $186.49M derived: sum of 3 quarters · filed 2025-03-05 | $247.30M 10-K · filed 2025-03-05 |
| 2023-09-30 | $55.50M 10-Q · filed 2024-11-04 | $102.48M derived: sum of 2 quarters · filed 2024-11-04 | $163.29M 10-Q · filed 2024-11-04 | $233.27M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $46.98M 10-Q · filed 2024-08-07 | $107.79M 10-Q · filed 2024-08-07 | $177.78M derived: sum of 3 quarters · filed 2025-03-05 | $235.34M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $60.81M 10-Q · filed 2024-05-08 | $130.79M derived: sum of 2 quarters · filed 2025-03-05 | $188.36M derived: sum of 3 quarters · filed 2025-03-05 | $248.95M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $69.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $127.54M derived: sum of 2 quarters · filed 2025-03-05 | $188.14M derived: sum of 3 quarters · filed 2025-03-05 | $245.66M 10-K · filed 2025-03-05 |
| 2022-09-30 | $57.56M 10-Q · filed 2023-11-03 | $118.16M derived: sum of 2 quarters · filed 2023-11-03 | $175.68M 10-Q · filed 2023-11-03 | $229.76M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $60.60M 10-Q · filed 2023-08-02 | $118.12M 10-Q · filed 2023-08-02 | $172.20M derived: sum of 3 quarters · filed 2024-02-28 | $217.65M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $57.52M 10-Q · filed 2023-05-05 | $111.60M derived: sum of 2 quarters · filed 2024-02-28 | $157.05M derived: sum of 3 quarters · filed 2024-02-28 | $212.83M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $54.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $99.53M derived: sum of 2 quarters · filed 2024-02-28 | $155.31M derived: sum of 3 quarters · filed 2024-02-28 | $218.69M 10-K · filed 2024-02-28 |
| 2021-09-30 | $45.45M 10-Q · filed 2022-11-02 | $101.23M derived: sum of 2 quarters · filed 2022-11-02 | $164.61M 10-Q · filed 2022-11-02 | $241.91M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $55.78M 10-Q · filed 2022-08-03 | $119.16M 10-Q · filed 2022-08-03 | $196.46M derived: sum of 3 quarters · filed 2022-08-03 | $250.31M derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-31 | $63.38M 10-Q · filed 2022-05-04 | $140.68M derived: sum of 2 quarters · filed 2022-05-04 | $194.53M derived: sum of 3 quarters · filed 2022-05-04 | $236.62M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $77.29M 10-K · filed 2021-02-26 | $131.15M derived: sum of 2 quarters · filed 2021-11-09 | $173.23M derived: sum of 3 quarters · filed 2021-11-09 | $225.57M 10-K · filed 2023-02-22 |
| 2020-09-30 | $53.85M 10-Q · filed 2021-11-09 | $95.94M derived: sum of 2 quarters · filed 2021-11-09 | $148.28M 10-Q · filed 2021-11-09 | $199.99M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $42.09M 10-Q · filed 2021-08-05 | $94.43M 10-Q · filed 2021-08-05 | $146.13M derived: sum of 3 quarters · filed 2021-08-05 | $184.57M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $52.34M 10-Q · filed 2021-05-06 | $104.05M derived: sum of 2 quarters · filed 2021-05-06 | $142.48M derived: sum of 3 quarters · filed 2021-05-06 | $180.46M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $51.71M 10-K · filed 2021-02-26 | $90.14M derived: sum of 2 quarters · filed 2021-02-26 | $128.12M derived: sum of 3 quarters · filed 2021-02-26 | $161.45M 10-K · filed 2022-02-24 |
| 2019-09-30 | $38.44M 10-K · filed 2021-02-26 | $76.42M derived: sum of 2 quarters · filed 2021-02-26 | $109.75M 10-Q · filed 2020-11-06 | $142.12M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $37.98M 10-K · filed 2021-02-26 | $71.31M 10-Q · filed 2020-08-07 | $103.68M derived: sum of 3 quarters · filed 2021-02-26 | $134.46M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $33.33M 10-K · filed 2021-02-26 | $65.70M derived: sum of 2 quarters · filed 2021-02-26 | $96.48M derived: sum of 3 quarters · filed 2021-02-26 | $143.51M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $32.37M 10-K · filed 2020-02-26 | $63.15M derived: sum of 2 quarters · filed 2020-02-26 | $110.18M derived: sum of 3 quarters · filed 2020-02-26 | $145.66M 10-K · filed 2021-02-26 |
| 2018-09-30 | $30.78M 10-K · filed 2020-02-26 | $77.81M derived: sum of 2 quarters · filed 2020-02-26 | $113.29M 10-Q · filed 2019-11-12 | $153.40M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $47.03M 10-K · filed 2020-02-26 | $82.52M 10-Q · filed 2019-08-07 | $122.62M derived: sum of 3 quarters · filed 2020-02-26 | $155.66M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $35.49M 10-K · filed 2020-02-26 | $75.59M derived: sum of 2 quarters · filed 2020-02-26 | $108.63M derived: sum of 3 quarters · filed 2020-02-26 | $137.84M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $40.11M 10-K · filed 2019-03-01 | $73.14M derived: sum of 2 quarters · filed 2019-03-01 | $102.35M derived: sum of 3 quarters · filed 2019-03-01 | $133.66M 10-K · filed 2020-02-26 |
| 2017-09-30 | $33.03M 10-K · filed 2019-03-01 | $62.24M derived: sum of 2 quarters · filed 2019-03-01 | $93.55M 10-Q · filed 2018-11-08 | $133.43M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $29.21M 10-K · filed 2019-03-01 | $60.52M 10-Q · filed 2018-08-07 | $100.40M derived: sum of 3 quarters · filed 2019-03-01 | $122.53M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $31.31M 10-K · filed 2019-03-01 | $71.19M derived: sum of 2 quarters · filed 2019-03-01 | $93.32M derived: sum of 3 quarters · filed 2019-03-01 | $115.91M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $39.88M 10-K · filed 2018-03-08 | $62.01M derived: sum of 2 quarters · filed 2018-03-08 | $84.60M derived: sum of 3 quarters · filed 2018-03-08 | $103.24M 10-K · filed 2019-03-01 |
| 2016-09-30 | $22.13M 10-K · filed 2018-03-08 | $44.72M derived: sum of 2 quarters · filed 2018-03-08 | $63.36M 10-Q · filed 2017-11-08 | $76.52M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $22.59M 10-K · filed 2018-03-08 | $41.23M 10-Q · filed 2017-08-09 | $54.40M derived: sum of 3 quarters · filed 2018-03-08 | $62.45M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $18.64M 10-K · filed 2018-03-08 | $31.81M derived: sum of 2 quarters · filed 2018-03-08 | $39.86M derived: sum of 3 quarters · filed 2018-03-08 | $50.42M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $13.16M 10-K · filed 2017-03-03 | $21.22M derived: sum of 2 quarters · filed 2017-03-03 | $31.78M derived: sum of 3 quarters · filed 2017-03-03 | $36.94M 10-K · filed 2018-03-08 |
| 2015-09-30 | $8.05M 10-K · filed 2017-03-03 | $18.61M derived: sum of 2 quarters · filed 2017-03-03 | $23.78M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $10.56M 10-K · filed 2017-03-03 | $15.72M 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $5.16M 10-K · filed 2017-03-03 | |||
| 2014-12-31 | $12.72M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |